678154-63-7

Upstream product

• 1606-67-3 1-aminopyrene 
• 625457-61-6 (2S)-N-{4-[(4'-carboxybutyl)oxy]-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 625457-60-5 5-{4-[(S)-2-(Bis-ethylsulfanyl-methyl)-pyrrolidine-1-carbonyl]-2-methoxy-5-nitro-phenoxy}-pentanoic acid methyl ester 
• 140647-02-5 (2S)-N-(4-hydroxy-5-methoxy-2-nitrobenzoyl)pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 127810-77-9 (2S)-N-[4-benzyloxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl dithioacetal 
• 5522-43-0 1-nitropyrene 

Downstream Products

• 678154-65-9 (2S)-N-{4-[N-(1''-pyrenyl)-butane-4'-carboxamide]-oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal 

Relevant academic research and scientific papers

Synthesis and antitumour activity of pyrene-linked pyrrolo [2,1-c][1,4]benzodiazepine hybrids

Pyrene-linked pyrrolobenzodiazepine hybrids have been synthesized that exhibit potential anticancer activity in a number of human tumour cell lines. These hybrids also exhibit much enhanced DNA-binding ability in comparison to the parent pyrrolobenzodiazepine ring system (DC-81).

PYRENE-LINKED PYRROLO[2,1--C][1,4]BENZODIAZEPINE HYBRIDS USEFUL AS ANTI-CANCER AGENTS

The present invention relates to a process for the preparation of novel pyrrolo [2,1 -c][1,4]benzodiazepine hybrids useful as antitumour agents. This invention also relates to a process for the preparation of new pyrrolo[2,1-c][1,4]benzodiazepine hybrids